## Ludovica Taglieri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2487807/publications.pdf

Version: 2024-02-01

933447 888059 16 350 10 17 citations g-index h-index papers 17 17 17 713 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Tissue Expression of Androgen Receptor Splice Variant 7 at Radical Prostatectomy Predicts Risk of Progression in Untreated Nonmetastatic Prostate Cancer. Oncology, 2021, 99, 251-255.	1.9	11
2	Design, Synthesis and Biological Evaluation of New Pyrimidine Derivatives as Anticancer Agents. Molecules, 2021, 26, 771.	3.8	14
3	Discovery of a pyrimidine compound endowed with antitumor activity. Investigational New Drugs, 2020, 38, 39-49.	2.6	13
4	The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells. Investigational New Drugs, 2018, 36, 28-35.	2.6	15
5	Growth arrest and apoptosis induced by kinesin Eg5 inhibitor K858 and by its 1,3,4-thiadiazoline analogue in tumor cells. Anti-Cancer Drugs, 2018, 29, 674-681.	1.4	7
6	Thyroid hormone regulates fibronectin expression through the activation of the hypoxia inducible factor 1. Biochemical and Biophysical Research Communications, 2017, 493, 1304-1310.	2.1	8
7	Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells. Oncology Letters, 2017, 14, 3832-3838.	1.8	12
8	Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer. Clinical Breast Cancer, 2017, 17, 34-40.	2.4	5
9	Circulating Neuregulin-1 and Galectin-3 can be Prognostic Markers in Breast Cancer. International Journal of Biological Markers, 2017, 32, 333-336.	1.8	14
10	The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells. Investigational New Drugs, 2016, 34, 399-406.	2.6	23
11	Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation. Tumor Biology, 2016, 37, 2603-2611.	1.8	9
12	Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients. Tumor Biology, 2016, 37, 3379-3387.	1.8	52
13	Taxane induced neuropathy in patients affected by breast cancer: Literature review. Critical Reviews in Oncology/Hematology, 2015, 96, 34-45.	4.4	71
14	Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review. Cancer Chemotherapy and Pharmacology, 2015, 76, 679-690.	2.3	21
15	Elderly woman with triple-negative metastatic breast cancer successfully treated with metronomic capecitabine. Anticancer Research, 2014, 34, 4287-91.	1.1	2
16	Chemotherapy of rare skin adnexal tumors: a review of literature. Anticancer Research, 2014, 34, 5263-8.	1.1	27